Form D · Pharmaceuticals
ACTUATE THERAPEUTICS, INC.
Fort Worth, TX · CIK 0001652935
Offering snapshot reported Jul 7, 2025 · SEC filing
- Reported sold
- $4.67M Offering amount: $9.33M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 27, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 7, 2025 | Initial | $4,665,479 | No comparison | 8 | SEC filing |
| Apr 10, 2025 | Initial | Yet to sell | No comparison | 1 | SEC filing |
| Mar 6, 2024 | Initial | $3,000,000 | No comparison | 1 | SEC filing |
| Dec 15, 2022 | Amendment | $19,336,491 | $8,166,491vs Oct 19, 2022 | 95 | SEC filing |
| Oct 19, 2022 | Initial | $11,170,000 | No comparison | 30 | SEC filing |
| Dec 10, 2020 | Initial | $14,482,301 | No comparison | 14 | SEC filing |
| Nov 14, 2019 | Amendment | $6,500,000 | $2,557,460vs Oct 15, 2019 | 17 | SEC filing |
| Oct 15, 2019 | Initial | $3,942,540 | No comparison | 14 | SEC filing |
| May 13, 2019 | Initial | $21,886,833 | No comparison | 21 | SEC filing |
| Sep 12, 2018 | Initial | $4,025,000 | No comparison | 18 | SEC filing |
| Mar 20, 2017 | Initial | $3,000,000 | No comparison | 2 | SEC filing |
| Feb 3, 2017 | Initial | $150,000 | No comparison | 1 | SEC filing |
| Oct 8, 2015 | Initial | $410,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-550871
Offering amount includes the aggregate gross proceeds that may be received in the future upon the cash exercise in full of warrants.
Source: Form D, filed Jul 7, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Alex Andrianopoulos | Director |
| Neil Bajpayee | Director |
| Aaron Glenn Louis Fletcher | Director |
| Aaron G.L. Fletcher | Director |
| Jason Keyes | Director |
| Leslie Wayne Kreis Jr. | Director |
| Leslie Kreis, Jr. | Director |
| Pascal Krotee | Director |
| Paul Lytle | Executive |
| Andrew Mazar | Executive |
| Amy Ronneberg | Director |
| Roger Sawhney | Director |
| Daniel Schmitt | Director, Executive |
| Todd Thomson | Director |
| Dan Zabrowski | Director |
| Daniel Zabrowski | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1751 River Run Suite 400
Fort Worth, TX, 76107
Phone: 817-887-8455
Fort Worth, TX, 76107
Phone: 817-887-8455